Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial
about
Recent advances in the management of mucormycosis: from bench to bedsideTherapeutic Drug Monitoring of Posaconazole: an UpdatePharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infectionsTherapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectivePosaconazole: an oral triazole with an extended spectrum of activityInvasive aspergillosis in the intensive care unitA case report of inhalation anthrax acquired naturallyTrypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental ModelIntensive care medicine research agenda on invasive fungal infection in critically ill patients.SREB, a GATA transcription factor that directs disparate fates in Blastomyces dermatitidis including morphogenesis and siderophore biosynthesis.Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects.Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study.Skin concentrations and pharmacokinetics of posaconazole after oral administration.Factors associated with mortality in transplant patients with invasive aspergillosisFungal infections in transplant and oncology patients.Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based methodSteady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational sPhase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia.Ultra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosing.Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, andSixty-year-old man with slowly expanding nodular plaque on the thighAntifungal clinical trials and guidelines: what we know and do not knowAnalysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantationInvasive fungal infections in solid organ transplant recipients.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Clinical hepatotoxicity associated with antifungal agents.Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis.Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity.Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapyPharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapyIsavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections.Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections.Relevance of timing for determination of posaconazole plasma concentrationsFailure of posaconazole therapy in a renal transplant patient with invasive aspergillosis due to Aspergillus fumigatus with attenuated susceptibility to posaconazoleEpidemiology and treatment approaches in management of invasive fungal infectionsPharmacokinetics and safety study of posaconazole intravenous solution administered peripherally to healthy subjects.Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer.Outcome analysis of invasive aspergillosis in hematologic malignancy and hematopoietic stem cell transplant patients: the role of novel antimold azoles
P2860
Q24642450-3F51FD91-DF92-45D0-BAAD-2FE5AE16D512Q26746016-C920C8B3-5923-4C86-9417-1079ED5DD657Q26771180-406DFE69-7C62-48F9-BDAC-38BB4E1A4FB1Q27009221-EA7A377E-6292-47DA-A6E1-E4C3DEA64522Q28291282-F3A03849-60A5-41BF-A622-854564E672C8Q28306909-526AC856-AFEC-4EC2-B43E-377D5B5F0860Q28388755-028A3F97-2738-4EC1-824C-DD69D159570EQ28553573-CBAFE3D9-1942-4102-85D2-4105829AF702Q30235457-6AB65592-70F4-4137-9FB0-57D7B336391CQ33549666-93FE01A5-D144-4597-99C9-8F9FE0CA7C13Q33798286-C099460B-C52E-4717-BC09-5465F02A7DDAQ33798313-AF5530BA-65DF-4EA4-8169-0B3D48A86B39Q33800526-B700E4B9-208A-460C-A005-460D9B2B753BQ33826421-D3F5AFED-530B-47DF-A531-00BE9C39B187Q33867013-508909BA-6D46-421A-8215-0471DFC4D0FCQ33896940-D6842B59-39F3-4D55-9993-02E4A431F483Q34108484-0CF806CF-E1F1-402D-8F03-3DB8919D3577Q34108650-F72FD419-0D1E-42C4-BF82-9C476EFE2302Q34288593-FA2C4B25-6679-4BAB-AC94-176F32232DBCQ34299092-79D56C04-02DC-4626-BFE2-71E3FE5EF4E2Q34309527-86A3F92A-0D09-4C59-B817-0AE8CF776202Q34309603-5B77AD1B-46D7-4168-9AB9-4D70075007E3Q34362577-596E0F4E-F4FA-427E-9572-FD736112555AQ34400255-E6CB2849-E1E2-4A26-8D55-2599254A4158Q34452574-446AA673-B9E0-4847-B2E5-394A1F55F96DQ34461693-7CE60D82-2AA3-41F3-81C5-5AEBBE6EA15FQ34532546-B2311FF6-59B5-49AE-9B63-1A05CF134B3EQ34546811-1CD310C4-ECCD-4CD5-B0D7-26E14D6596B1Q34596750-56BC11E5-74D5-4F16-867A-347E16E78D51Q34596950-9F44AEE5-8403-4E6E-A3E1-9E3BC96258B6Q34737174-7239EA97-6BB0-4880-96CB-A6A2CA9072F9Q34754956-A5F1682B-9041-449B-933B-10DA1752C161Q34900399-777DB67E-095B-401E-8609-E75670CB720CQ35026481-DB58370B-09D4-414B-AD91-1302189D3214Q35065721-F39BE00C-5524-4A7F-BB7D-6B559A5BD3C5Q35065903-8FAD6C02-9676-4CA6-B82C-C03EC2196FE1Q35089772-1DC3A24B-99FC-40D4-8AB0-7A9820C6140FQ35105840-DD34BD08-D2F7-48C2-A7EC-BD0134FD7723Q35262607-346E81C4-8653-430E-9D25-25BA42AA39A6Q35584615-033E6217-162E-4DCC-A3E4-0C555A65CB00
P2860
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Treatment of invasive aspergil ...... an externally controlled trial
@ast
Treatment of invasive aspergil ...... an externally controlled trial
@en
Treatment of invasive aspergil ...... an externally controlled trial
@nl
type
label
Treatment of invasive aspergil ...... an externally controlled trial
@ast
Treatment of invasive aspergil ...... an externally controlled trial
@en
Treatment of invasive aspergil ...... an externally controlled trial
@nl
prefLabel
Treatment of invasive aspergil ...... an externally controlled trial
@ast
Treatment of invasive aspergil ...... an externally controlled trial
@en
Treatment of invasive aspergil ...... an externally controlled trial
@nl
P2093
P2860
P3181
P356
P1476
Treatment of invasive aspergil ...... an externally controlled trial
@en
P2093
Amelia Langston
Arnold Louie
Brahm H Segal
Catherine Hardalo
Charles S White
David A Stevens
Gavin Corcoran
Gerald R Donowitz
Gopal Krishna
Issam Raad
P2860
P3181
P356
10.1086/508774
P407
P577
2007-01-01T00:00:00Z